SGLT2-I in the Hospital Setting: Diabetic Ketoacidosis and Other Benefits and Concerns

Joshua A. Levine, Susan L. Karam, Grazia Aleppo*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

17 Scopus citations


Purpose of Review: Sodium-glucose cotransporter 2 (SGLT2) inhibitors are the newest class of antihyperglycemic agents. They are increasingly being prescribed in the outpatient diabetic population. In this review, we examine the risks and benefits of continuation and initiation of SGLT2 inhibitors in the inpatient setting. Recent Findings: There are currently no published data regarding safety and efficacy of SGLT2 inhibitor use in the hospital. Outpatient data suggests that SGLT2 inhibitors have low hypoglycemic risk. They also decrease systolic blood pressure and can prevent cardiovascular death. The EMPA-REG study also showed a decrease in admissions for acute decompensated heart failure. There have been increasing cases of diabetic ketoacidosis, and specifically the euglycemic manifestation, associated with SGLT2 inhibitors use. We present two cases of inpatient SGLT2 inhibitor use, one of continuation of outpatient therapy and one of new initiation of therapy. We then discuss potential risks and methods to mitigate these as well as benefits of these medications in the inpatient setting. Summary: We cautiously suggest the use of SGLT2 inhibitors in the hospital. However, these must be used judiciously and the practitioner must be aware of euglycemic diabetic ketoacidosis and its risk factors in this population.

Original languageEnglish (US)
Article number54
JournalCurrent Diabetes Reports
Issue number7
StatePublished - Jul 1 2017


  • DKA
  • Euglycemic DKA
  • Heart failure
  • Inpatient
  • SGLT2 inhibitor

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism


Dive into the research topics of 'SGLT2-I in the Hospital Setting: Diabetic Ketoacidosis and Other Benefits and Concerns'. Together they form a unique fingerprint.

Cite this